{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:02:34Z","timestamp":1770894154935,"version":"3.50.1"},"reference-count":18,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2009,5,18]],"date-time":"2009-05-18T00:00:00Z","timestamp":1242604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Response and survival in 96 patients with secondary acute myeloid leukemia (sAML) who received aggressive induction chemotherapy was reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>The median follow\u2010up of survivors was 2.3 years. A total of 70 (73%) patients achieved a morphologic complete remission (CR) confirmed by absence of leukemic blasts by flow cytometry.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>For all 96 patients, the median event\u2010free survival (EFS) was 8 months, and overall survival (OS) was 13.6 months (range, 1\u2010119 months). Eight patients died shortly after induction therapy because of disease or side effects, and 13 are currently in continuous first remission. The median disease\u2010free survival (DFS) for all 70 patients who achieved a morphologic CR was 9 months (range, 1\u201051 months), with a 64% chance of surviving 1 year. Patients with AML after previous chemotherapy or radiation therapy had a higher morphologic remission rate compared with those arising from myelodysplastic syndrome or myeloproliferative disease (82% vs 62%; <jats:italic>P<\/jats:italic> = .027). However, among the patients from the 2 groups who attained a morphologic remission, there was no difference in terms of CR rate (<jats:italic>P<\/jats:italic> = .94), DFS, EFS, or OS (<jats:italic>P<\/jats:italic> = .55, .83, and .71, respectively). This is a similar DFS to the group of 7 patients who went directly to ablative allogeneic transplant rather than having induction therapy first. In this population of patients who received aggressive chemotherapy, Charlson comorbidity index or a higher number of factors recognized as high risk in leukemia patients did not affect the chance of OS, DFS, and EFS, although having more recognized leukemia risk factors was related to a lower chance of surviving 1 year. However, it is important to note that those with higher comorbidity indexes were underrepresented in this aggressively treated cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>The data from the current study demonstrate that many patients with sAML can tolerate aggressive induction therapy and attain remission, but duration of response and the chance of long\u2010term survival remain poor. Cancer 2009. \u00a9 2009 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.24379","type":"journal-article","created":{"date-parts":[[2009,5,18]],"date-time":"2009-05-18T16:23:25Z","timestamp":1242663805000},"page":"2922-2929","source":"Crossref","is-referenced-by-count":26,"title":["Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia"],"prefix":"10.1002","volume":"115","author":[{"given":"David A.","family":"Rizzieri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny A.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Broadwater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos M.","family":"Decastro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakash","family":"Dev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Beaven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Lagoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon P.","family":"Gockerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson J.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph O.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,5,18]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_2_6_3_2","first-page":"40","volume-title":"IARC Monographs on the Evaluation of Carcinogenic Risks to Humans","author":"International Agency for Research on Cancer","year":"1987"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)91524-0"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5340.1068"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70340-3"},{"key":"e_1_2_6_7_2","first-page":"435","article-title":"Therapy\u2010related leukemia and myelodysplastic syndrome","volume":"14","author":"Kantarjian HM","year":"1987","journal-title":"Semin Oncol."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909303411407"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood.V89.9.3323","article-title":"Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard therapy. A Southwest Oncology Group study","volume":"89","author":"Leith CP","year":"1997","journal-title":"Blood."},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1182\/blood.V91.10.3607","article-title":"A double\u2010blind placebo\u2010controlled trial of granulocyte colony\u2010stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study","volume":"91","author":"Godwin JE","year":"1998","journal-title":"Blood."},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0354"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198704233161702"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109057929"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_6_15_2","first-page":"1805","article-title":"Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) after MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC\u2010LCG)","volume":"9","author":"de Witte T","year":"1995","journal-title":"Leukemia."},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(96)00116-6"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.3.548"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1302"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402591"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24379","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T21:11:23Z","timestamp":1760303483000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,18]]},"references-count":18,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1002\/cncr.24379"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24379","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,18]]}}}